Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-small-cell Lung
- Registration Number
- NCT00040638
- Lead Sponsor
- Telik
- Brief Summary
The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Histologic or cytologic diagnosis of non-small cell lung carcinoma
- Progressed while on or after treatment on platinum-based regimen
- Patients may not have had more than one prior cytotoxic chemotherapy regimen
- Stage IV or IIIB
- Age at least 18 years
- Adequate liver and kidney function
- Adequate bone marrow function
Exclusion Criteria
- Pregnancy or lactation
- Unstable medical conditions
- Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286
- CNS metastasis unless controlled by treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
UCLA Medical Center
🇺🇸Los Angeles, California, United States
M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
Arizona Cancer Center🇺🇸Tucson, Arizona, United States